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volumeAbstract Background: Mammographic density has been shown to be a strong independent
predictor of breast cancer and a causative factor in reducing the sensitivity of mammography.
There remain questions as to the use of mammographic density information in the context of
screening and risk management, and of the association with cancer in populations known to
be at increased risk of breast cancer.
Aim: To assess the association of breast density with presence of cancer by measuring
mammographic density visually as a percentage, and with two automated volumetric methods,
Quantra and VolparaDensity.
Methods: The TOMosynthesis with digital MammographY (TOMMY) study of digital breast
tomosynthesis in the Breast Screening Programme of the National Health Service (NHS) of
the United Kingdom (UK) included 6020 breast screening assessment cases (of whom 1158
had breast cancer) and 1040 screened women with a family history of breast cancer (of whom
two had breast cancer). We assessed the association of each measure with breast cancer risk in
these populations at enhanced risk, using logistic regression adjusted for age and total breast
volume as a surrogate for body mass index (BMI).
Results: All density measures showed a positive association with presence of cancer and all
declined with age. The strongest effect was seen with Volpara absolute density, with a signif-
icant 3% (95% CI 1e5%) increase in risk per 10 cm3 of dense tissue. The effect of Volpara
volumetric density on risk was stronger for large and grade 3 tumours.
Conclusions: Automated absolute breast density is a predictor of breast cancer risk in popula-
tions at enhanced risk due to either positive mammographic findings or family history. In the
screening context, density could be a trigger for more intensive imaging.
ª 2017 The Authors. Published by Elsevier Ltd. This is an open access article under the CC
BY license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
High breast density has been shown to be a strong, in-
dependent risk factor for breast cancer [1e5]. It has been
reported that women with a high breast density
compared to women with a low breast density have a
four- to sixfold increased risk of developing the disease
[6e10]. High breast density has also been linked to
cancers which are larger and have positive lymph nodes,
although the reported results vary considerably [11e15]
and high breast density has been found in women with
cancers diagnosed outside of the screening programme
[1,4,16e18]. One possible explanation for the latter is a
masking bias, in that dense breast tissue could render
breast cancers less sensitive to screen detection, leading
to a higher incidence of breast cancer in those previously
screened negative. A number of studies, however, indi-
cate that this is only partly responsible for the observed
increased cancer risk with high density [2,6,19]. Indeed,
density has been shown to be a risk factor for screen-
detected as well as symptomatic cancers [4,6].
There is no consensus on the most useful measure of
breast composition in risk prediction, risk management
and surveillance decisions. One meta-analysis found that
absolute rather than proportional estimates of breast
density are more strongly predictive of risk [2], whereas
another found the opposite [20].
Younger, pre- or perimenopausal women are known
to have a higher proportion of dense breast tissue, asbreast density decreases with age [21,22]. The National
Health Service Breast Screening Programme (NHSBSP)
in the United Kingdom (UK) invites women aged 50e70
every 3 years for two-view digital mammography which
is double read [23]. Extension of the age range to 47e73
is currently under investigation. Women at moderate
risk with a significant family history of breast cancer
may be screened annually from age 40 [24].
Issues outstanding in breast density include:
 identifying the breast density measure (percent density,
absolute quantity of dense tissue) most strongly associated
with breast cancer;
 the method of measurement (visual, automated volumetric
measures, automated area measures) most strongly associ-
ated with cancer;
 age and tumour-specific associations with risk;
 the extent to which density contributes risk information in
subjects already known to be at higher risk of breast cancer,
such as women attending for screening who are recalled for
assessment due to a suspicious mammographic finding (and
which measure of density is most suitable in this
population).
Also, it is worth noting that the identification of
mammographic density as a risk factor took place in the
predigital era, and most of the studies demonstrating the
effect of density on breast cancer risk pertain to mea-
sures from film/screen mammography. There is a current
need to demonstrate and validate measures of breast
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equally strongly associated with breast cancer risk.
In this study, we assess the associations of visual
percent density assessment and automated volumetric
breast composition measures with breast cancer risk in
women recalled for assessment in the general population
screening programme and in women aged 40e50 years
under increased mammographic surveillance due to a
family history of breast cancer. Women in the latter
category are those at moderate or high familial risk of
breast cancer, defined as a lifetime risk of at least 17%
[24].
2. Materials and methods
In the TOMMY trial (TOMosynthesis with digital
MammographY in the UK NHS Breast Screening
Programme), participants were recruited from six cen-
tres [25]. They comprised women aged 47e73 years
recalled to an assessment clinic and also women below
50 years of age with a family history of breast cancer
who attended annual mammography screening. Data
were available for 6020 breast screening assessment
cases (of whom 1158 had breast cancer) and 1040 family
history screenees (of whom two had breast cancer), who
had been recruited between February 2011 and August
2013. On recruitment, each woman had a two-dimen-
sional (2D) mammogram as part of the digital breast
tomosynthesis (DBT) examination. Both the DBT and
the standard 2D imaging were performed as a single
procedure at the same breast compression on a Hologic
Selenia Dimensions Digital Mammography Unit
(Hologic Inc., Bedford, MA, United States of America ).
These research images were read by trained radiologists
blinded to the knowledge of cancer status of the woman-
screenee, using full field digital mammography (2D) and
the DBT. To score visual density, readers used a visual
analogue scale (VAS), requiring them to make a mark
on a 10-cm line which was subsequently converted to a
percentage score between 0% and 100% [26]. Visual
percent density was estimated for each woman by one of
26 image readers using information from the available
mammograms from the examination without knowledge
of cancer status (although the readers were of course
able to see abnormalities). In the family history cases,
density was also scored by an additional reader and the
mean of the two results was used. Although visual
assessment of density is subject to inter- and intra-
observer variability [5,27], reasonable agreement was
observed between the readers, with absolute differences
of less than 10% in 70% of cases [28]. The readers had a
minimum of two years’ experience of reading at least
5000 cases annually in the NHSBSP.
In addition to radiological, clinical and pathological
data, we also measured breast density using two auto-
mated volumetric tools, Volpara version 1.4.2 [29] andQuantra version 2.0 [30] and by visual assessment. All
breast density measures were performed on 2D
mammography.
Age was coded for 6985 (99%) of the 7060 cases. Ages
of the subjects ranged from 29 to 85, with 96% of sub-
jects aged 40e70. Volpara breast composition data were
available for 7019 of the 7060 cases (1157 of the 1160
cancer patients and 5862 non-cancer patients). Corre-
sponding Quantra data were available for 7005 of the
cases (1156 cancer patients and 5849 non-cancer pa-
tients). Visually assessed percent density was available
for 6969 cases (including 1153 cancer patients). None of
the three methods gave a complete set of results for all
cases as the software tools did not produce scores for
every image analysed and other clinical pressures occa-
sionally took precedence over the requirement to give a
density score. However, this occurred in only 0.6% and
0.8% of cases in Volpara and Quantra respectively.
The output of both software tools gave measurements
of total breast volume, dense fibroglandular volume and
percent volumetric breast density for each image. The
craniocaudal (CC) and the mediolateral-oblique (MLO)
images of each breast were analysed. To obtain a single
score for each woman, the CC and MLO scores were uti-
lised as follows. For cases where no cancer was assessed as
beingpresent, the largest breast volumeandfibroglandular
volume for each breast (either from the CC orMLO view)
were determined and the average of each of these volumes
of the two breasts were calculated. For cases where cancer
was confirmed, results were used from the contralateral
breast. If no contralateral datawere available, results from
the affected breast were used. This occurred for one cancer
case in the Quantra data (0.1% of cancers) and 14 cases in
the Volpara (1% of cancers). Volumetric percent density
was calculated, as 100 times the ratio of the fibroglandular
tissue volume to the overall breast volume.
To evaluate the association of breast composition
measures with risk, data were analysed by logistic
regression with breast cancer as the outcome variable
and the various density and volume measures as pre-
dictor variables, adjusted for age. A major negative
confounder of area or volumetric percent density is
body mass index (BMI). In the NHSBSP, weight and
height are not traditionally recorded. We had, however,
weight and height data for a small subset of 178 recruits
for which we calculated BMI. While this did not provide
sufficient data to adjust the regression models, we ana-
lysed this subset and found that:
(1) BMI and total breast volume as measured by Volpara
had very similar negative correlations with percent
density measures; and
(2) within this subset of the data, adjusting the effects of
percent density measures on breast cancer risk for total
breast volume gave almost identical results to adjusting
for BMI.
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We then compared the predictive potential of the
measures using standardised logistic regression co-
efficients, so that all measures pertained to the same
scale. Using the most predictive measure, we then esti-
mated effects in subgroups of age, invasive status, node
status, size and grade of the cancers diagnosed, all
determined histologically, radiological features (mass,
calcification, or either asymmetry or architectural
distortion, as determined by the readers), and detection
status by 2D mammography and DBT. Data were
analysed using STATA version 10.0 [31].
3. Results
Table 1 shows the mean and standard deviation of
breast composition measures using Volpara, by age,
cancer status and non-cancer source (assessment or
family history screenee). The dense tissue volume was
generally higher in cancer cases than in non-cancerTable 1
Means (SD’s) of breast composition measures using the Volpara volumetri
age and diagnostic group, in 6944 assessment cases, including 1149 cancer
Age (years) Breast composition measure Mean (SD) f
Cancers
<50 Breast volume (cm3) 1063 (663)
Dense volume (cm3) 111 (53)
% Density 13 (7)
No. of subjects 29
50e59 Breast volume (cm3) 1153 (670)
Dense volume (cm3) 94 (54)
% Density 10 (6)
No. of subjects 460
60 Breast volume (cm3) 1092 (562)
Dense volume (cm3) 77 (44)
% Density 8 (4)
No. of subjects 660
Table 2
Means (SD’s) of breast composition measures using Quantra volumetric br
6930 assessment cases, including 1148 cancers in the UK Breast Screening
Age (years) Breast composition measure Mean (SD) f
Cancers
<50 Breast volume (cm3) 1118 (723)
Dense volume (cm3) 143 (99)
% Density 14 (7)
No. of subjects 29
50e59 Breast volume (cm3) 1195 (670)
Dense volume (cm3) 131 (93)
% Density 12 (6)
No. of subjects 459
60 Breast volume (cm3) 1126 (582)
Dense volume (cm3) 104 (71)
% Density 9 (5)
No. of subjects 660cases, and declined with age in all groups. The percent
density showed the same tendencies, although less
markedly. Table 2 shows the corresponding figures for
Quantra, exhibiting a similar pattern. Table 3 shows the
mean and standard deviation of visually assessed
percent density by age, cancer status and non-cancer
source. This showed a distinct decline with age for
both cancer and non-cancer cases. However, in those
aged 60 or over, the cancer cases had a slightly lower
percent density than the non-cancer cases.
Table 4 shows the age-adjusted standardised logistic
regression coefficients for the automated measures of
dense tissue volume and the visually assessed percent
density. The three measures that used percentages were
also adjusted for Volpara total breast volume. The
strongest effect in terms of both coefficient and signifi-
cance was that of Volpara absolute dense tissue volume,
corresponding to a 3% increase in the odds of cancer per
additional 10 cm3 of dense tissue (95% CI 1e5%). The
effect of Quantra dense tissue volume was slightlyc breast density measurement (Volpara Health Technologies Ltd), by
s in the UK Breast Screening Programme.
or population
Assessment
non-cancers
Family history
non-cancers
All
non-cancers
1027 (673) 1041 (668) 1037 (669)
101 (67) 101 (61) 101 (63)
12 (6) 12 (7) 12 (7)
313 942 1255
1034 (614) 983 (597) 1033 (613)
84 (50) 84 (51) 84 (50)
9 (5) 10 (5) 10 (5)
3092 43 3135
1010 (557) 582 (75) 1009 (556)
73 (43) 53 (20) 73 (43)
8 (4) 9 (2) 8 (4)
1402 3 1405
east density measurement (Hologic), by age and diagnostic group, in
Programme.
or population
Assessment
non-cancers
Family history
non-cancers
All
non-cancers
1075 (696) 1088 (681) 1085 (685)
142 (128) 137 (99) 138 (107)
14 (7) 14 (7) 14 (7)
313 938 1251
1079 (636) 1044 (602) 1078 (636)
114 (99) 111 (82) 114 (88)
11 (6) 13 (9) 11 (6)
3088 43 3131
1054 (570) 612 (121) 1052 (570)
97 (76) 57 (41) 97 (76)
9 (5) 9 (5) 9 (5)
1397 3 1400
Table 3
Means (SD’s) of visually assessed percent density, by age and diag-
nostic group, in 6969 assessment cases, including 1153 cancers in the
UK Breast Screening Programme.
Age
(years)
Quantity Mean (SD) for population
Cancers Assessment
non-cancers
Family
history
non-
cancers
All
non-
cancers
<50 % Density 46 (19) 43 (18) 42 (22) 42 (21)
No. of subjects 29 314 915 1229
50e59 % Density 42 (22) 40 (21) 37 (18) 40 (21)
No. of subjects 461 3067 41 3108
60 % Density 33 (19) 35 (20) 40 (22) 35 (20)
No. of subjects 663 1432 47 1479
Table 4
Age-adjusted standardised logistic regression coefficients for effects of
Volpara (Volpara Health Technologies Ltd), Quantra (Hologic) and
visually assessed breast composition measures on risk of breast cancer
in approximately 6900 (varying depending on numbers with missing
data) assessment cases in the UK Breast Screening Programme.
Breast composition
measure
Standardised
logistic
regression
coefficient
95% CI Exact significance
Volpara Absolute dense
volume
0.16 0.09e0.22 p Z 0.000002
Percent dense
volume
0.09 0.00e0.17 p Z 0.04
Quantra Absolute dense
volume
0.15 0.09e0.22 p Z 0.000003
Percent dense
volume
0.14 0.06e0.21 p Z 0.0003
Visual Percent dense
area
0.09 0.01e0.16 p Z 0.02
Table 6
Odds ratios per 10 cm3 of dense tissue as measured by Volpara (Vol-
para Health Technologies Ltd) within subgroups of 7019 assessment
cases in the UK Breast Screening Programme.
Variable Subgroup OR per
10 cm3
95% CI Significance
Age (years) <50 1.02 0.97e1.07 p Z 0.3
50e59 1.04 1.02e1.07 p < 0.001
60 1.02 1.00e1.05 p Z 0.03
Dominant
radiological
feature
Mass 1.00 0.96e1.04 p Z 0.8
Calcification 1.04 1.02e1.07 p < 0.001
Asymmetry/
architectural
distortion
1.03 1.00e1.06 p Z 0.03
Recalled by 2D
mammography
No 1.04 1.00e1.07 p Z 0.01
Yes 1.03 1.01e1.05 p < 0.001
Recalled by
2D þ DBT
No 1.01 0.96e1.06 p Z 0.5
Yes 1.03 1.01e1.05 p Z 0.001
Recalled by synthetic
2D þ DBT
No 1.02 0.98e1.06 p Z 0.4
Yes 1.03 1.00e1.05 p Z 0.002
Invasive status Non-invasive 1.03 1.00e1.06 p Z 0.01
Invasive 1.03 1.01e1.05 p < 0.001
Node status of
tumour (invasive
only)
Negative 1.02 1.00e1.05 p Z 0.01
Positive 1.03 1.01e1.06 p < 0.001
Size of tumour
(invasive only)
1e10 mm 1.01 0.98e1.04 p Z 0.6
11e20 mm 1.03 1.00e1.05 p Z 0.004
>20 mm 1.06 1.03e1.08 p < 0.001
Histological grade of
tumour (invasive
only)
1 1.03 1.00e1.06 p Z 0.01
2 1.02 1.00e1.05 p Z 0.02
3 1.04 1.00e1.08 p Z 0.001
Total population e 1.03 1.01e1.05 p < 0.001
Notes Asymmetry/architectural distortion: forms of asymmetrical
breast density visible from the mammogram.
S.W. Duffy et al. / European Journal of Cancer 88 (2018) 48e5652weaker but very similar. The confidence intervals on the
two standardised estimates indicate that the difference is
compatible with chance.
Table 5 shows the age-adjusted odds ratios by quin-
tile of the two measures of dense tissue volume, both
showing a moderate but highly significant increase in
risk across quintiles. There was an approximate
doubling of risk for the highest quintile compared to the
lowest.
Table 6 shows the results of subgroup analyses of the
association of Volpara dense tissue volume with breastTable 5
Odds ratios for breast cancer by quintile of absolute dense volume by
Volpara (Volpara Health Technologies Ltd) and Quantra (Hologic) in
approximately 6900 (depending on numbers with missing data)
assessment cases in the UK Breast Screening Programme.
Volpara dense
volume (cm3)
OR 95% CI Quantra dense
volume (cm3)
OR 95% CI
<48 1.00 e <54 1.00 e
48e63.99 1.45 1.17e1.79 54e78.99 1.46 1.17e1.82
64e82.99 1.53 1.23e1.90 79e110.99 1.65 1.32e2.05
83e114.99 1.50 1.19e1.86 111e159.99 1.63 1.30e2.04
115 1.88 1.50e2.35 160 2.06 1.65e2.57cancer risk. For the most part, the effect of the volume
of dense tissue was similar in subgroups to that overall,
but a number of observations arise. The increased risk
with this measure was for the most part apparent within
the subgroups considered. The effect was slightly higher
in the presence of calcifications, in tumours missed by
2D mammography, in node positive tumours, in larger
tumours (>20 mm, and to a lesser extent in tumours of
size 11e20 mm) and in grade 3 cancers. For the radio-
logical indications, the effect of density on risk of tu-
mours appearing as calcifications was statistically
significant, and for tumours appearing as either asym-
metry or architectural distortion the effect was of
borderline significance.
4. Discussion
We found that automated volumetric measures of
mammographic density added significantly to estima-
tion of breast cancer risk in subjects already known to
be at enhanced risk due to a screening finding or to
family history. This adds to the evidence of breast
density as a robust predictor of breast cancer risk.
Notably, we found that the automated absolute mea-
sures were more strongly predictive of risk in this pop-
ulation than visually assessed percent density. The fact
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density may have a role in risk management at popu-
lation level. The NHSBSP screens more than two
million women per year and, clearly to be practicable,
any breast composition risk marker would have to be
automatically derived with minimal human resource
implications. Both commercially available products,
Volpara and Quantra, showed predictive potential, with
Volpara slightly stronger. Our risk gradients were not as
strong as observed by others [32]. This may be due to the
fact that our non-cancer cases were at enhanced risk due
to recall for assessment or family history and therefore
may have had higher breast density than general pop-
ulation controls. Also, our study data did not include
interval cancers. There are a higher proportion of in-
terval cancers in dense breasts, and if these had been
included this would have likely increased the risk
gradient to the expected level. In a single Dutch
screening centre of women in the 50e75 year old cate-
gory, including interval cancers, the highest quartile of
absolute density had a 2.5-fold risk compared to the
lowest quartile [33].
We did not have data on BMI, except for a small
minority of cancers, so could not adjust for this in our
analysis. However, as reported in the Appendix, in the
subset with BMI data, total breast volume as assessed by
Volpara displayed the same properties as BMI in terms
of correlation with other breast composition measures
and of adjustment of percent density measures. This
raises an interesting issue. Traditionally, estimates of the
effect of percent mammographic density on breast can-
cer risk are adjusted for BMI as the two are known to be
strongly negatively confounded. The reason for this
confounding may be the structural negative relationship
between percent density and total breast size, since the
latter is essentially the denominator of the former. Thus,
BMI may be a surrogate for total breast volume rather
than the reverse. In any case, results in the Appendix
suggest that adjustment for total breast volume ach-
ieves the same effect in this context as adjustment for
BMI.
The finding that breast density is associated with
increased risk of breast cancer in this specific population
already known to be at enhanced risk is novel, but
consistent with the literature. While studies vary in their
findings as to which measure of density is most predic-
tive of risk, the finding that increased levels of density
are associated with increased risk of breast cancer is
almost universal [1e12]. It has generally been observed
that quantitative measures of density are stronger pre-
dictors of breast cancer risk than qualitative [2,9]. It is
known that density also impairs mammographic accu-
racy, which can mean that some tumours are missed at
screening due to masking by high levels of density, and
therefore subsequent incidence in this group is increased
[13]. However, results from several studies indicate that
there is also an effect of increased risk of breast cancerdue to density which is not attributable to a masking
phenomenon [2,4,6,19]. Recent results suggest that ab-
solute measures of dense tissue area or volume have
greater predictive power than percentage measures
[34e36], but this is not universally observed [37].
In this study, we found that absolute dense tissue
volume was a stronger predictor than percent density.
We also found that dense tissue volume was slightly
more strongly predictive of cancers with unfavourable
prognostic factors such as larger than 20 mm in size,
grade 3 and node positive cancers. Confidence intervals
were relatively wide in these subgroups, so interpreta-
tion should be done cautiously. Whether this is due to
chance, to a true difference in the biological effect of
high levels of density or to the masking effect of dense
tissue remains to be seen, but it has been observed
elsewhere [11e14,38,39]. Again, inclusion of interval
cancers (not possible in this study) would clarify issues
of masking. A number of other studies, however, have
not found a stronger association with less favourable
biological tumour attributes [40e43]. Two of the latter
studies did find an increased effect of density on interval
cancers which would be expected to be larger and more
likely to be node positive [41,43]. The result may be
particular to screen-detected cancers, since Ding et al.
[41] did find an increased effect of density on risk of
larger tumours among their screen-detected cancers.
This may have management or diagnostic implications.
In our set of screen-detected cancers, larger, node pos-
itive cancers were found in the breasts with highest
density. Some of these may have been missed at previous
screens as a result of high density and had diagnosis
considerably delayed. The UK breast screening pro-
gramme has a relatively long three yearly screening in-
terval. Therefore, screening frequency could be
increased for women with more dense fibroglandular
tissue in order to find the tumours at a smaller size, or
DBT could be used in those women with highest breast
volumetric density, as the addition of DBT was found to
improve diagnostic accuracy in women with dense
breasts in the TOMMY trial [25]. The adequacy of
screening frequency depending on breast density (and
possibly on other risk factors) is being currently studied
by others, such as the PROCAS study [44].
It is worth noting that women with dense breasts
were more likely to undergo biopsy. In the lowest
quintile of Volpara absolute dense volume, 33% of the
assessment cases had a biopsy, whereas in the highest
quintile, the figure was 41%. It is possible that the
availability of DBT (and perhaps other imaging mo-
dalities) at assessment might avoid some unnecessary
biopsies. Of the non-cancer cases who underwent bi-
opsy, 39% were not marked for recall in rereading by
DBT (compared to 29% in rereading with 2D
mammography).
The study population was a mix of breast screening
assessment cases (85%) and family history screening
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breast cancer by definition. In the TOMMY trial [25],
family history screenees were included to provide a
group of cases with higher breast density as a result of
their lower average age for subanalysis of the impact of
breast density on the diagnostic accuracy of DBT, and
have therefore been kept in our analysis. Results were
essentially unchanged when we excluded the family
history screenees, so they apply specifically to women
recalled for assessment due to a suspicious screening
mammogram. One would expect a smaller effect of
density on risk in assessment cases as these would be
likely to have higher levels of density on average than
the general population, as women with denser breasts
have mammography results harder to read and tend to
be recalled more often [45]. Our results indicate that the
effect in this group, while smaller than observed in the
general screened population [2], is by no means negli-
gible. There may be a role for density in the subsequent
surveillance and risk management of women recalled for
assessment but found not to have breast cancer. Opti-
misation of the screening technique such as the addition
of DBT or increased frequency of screening may be
relevant. Alternatively, women could be counselled and
offered strategies to reduce their volume of fibro-
glandular tissue by other lifestyle changes such as
stopping hormone replacement therapy, or by primary
chemoprevention.
In conclusion, we found that dense breast tissue
volume as measured by automated methods was a sig-
nificant predictor of breast cancer risk in women with a
suspicious screening mammogram or a family history.
This is consistent with findings that various measures of
density can add predictive power to currently used
breast cancer risk assessment tools [46,47]. The fully
automated methods can be used with little addition to
human resource costs. Density is likely to have a role in
risk management both in a population screening context
and in management and surveillance of women at
increased risk of breast cancer, and in particular can
assist in identifying populations who might benefit from
enhanced surveillance or primary prevention in-
terventions [47].
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